HKUST CRISPR-Cas12a Innovation Revolutionizes Programmable RNA Targeting

HKUST's Groundbreaking Reprogramming of CRISPR-Cas12a Ushers in a New Era for RNA Manipulation

The Hong Kong University of Science and Technology (HKUST) has once again positioned itself at the forefront of global biotechnology innovation with a transformative advancement in CRISPR technology. Researchers led by Professor I-Ming Hsing from the Department of Chemical and Biological Engineering and the Division of Life Science have developed a novel DNA-guided CRISPR-Cas12a system capable of programmable recognition and cleavage of RNA molecules. Published in the prestigious journal Nature Biotechnology on May 1, 2026, this discovery flips the conventional paradigm of CRISPR effectors, which traditionally use RNA guides to target DNA, and opens up unprecedented possibilities for RNA-specific interventions.

This achievement not only highlights HKUST's prowess in interdisciplinary research—blending chemical engineering, structural biology, and synthetic biology—but also underscores China's rising dominance in life sciences. As higher education institutions in the region invest heavily in biotech infrastructure and talent, breakthroughs like this from HKUST exemplify how university-led research is driving practical applications in diagnostics, therapeutics, and beyond.

At its core, CRISPR-Cas12a, also known as Cpf1, is a type V CRISPR-associated protein renowned for its single-guide RNA (crRNA) dependent cleavage of double-stranded DNA adjacent to a protospacer adjacent motif (PAM), typically TTTV. Unlike the more widely used Cas9, Cas12a produces staggered cuts, processes its own crRNA array, and exhibits collateral trans-cleavage activity useful for diagnostics. However, its reliance on RNA guides limits flexibility in scenarios where DNA stability or modular design is preferred. The HKUST team addressed this by engineering synthetic CRISPR DNA (crDNA), a DNA molecule mimicking the PAM-duplex structure of conventional targets. This crDNA binds apo-Cas12a via PAM interactions with the PI, WED, and REC1 domains, forming a stable deoxyribonucleoprotein (DNP) complex that then recruits and cleaves complementary single-stranded RNA targets.

Decoding the Molecular Mechanism: From PAM Recognition to RNA Cleavage

The ingenuity of this system lies in repurposing Cas12a's activation pathway. Normally, crRNA pseudoknot formation stabilizes the ribonucleoprotein complex for DNA binding. Here, crDNA occupies the dsDNA-binding groove without a pseudoknot, relying on PAM-dependent engagement for initial activation. Cryo-electron microscopy (cryo-EM) at 3.17 Å resolution revealed the ternary AsCas12a-crDNA-RNA complex, where a 20-base-pair DNA-RNA heteroduplex forms in the guide channel. The RuvC nuclease domain cleaves the RNA at positions 2, 5, and 6 nucleotides downstream of the spacer, confirming Mg²⁺-dependent phosphodiester bond hydrolysis.

Biophysical assays further validated the mechanism. Electrophoretic mobility shift assays (EMSA) showed tight binding (K_d ~14 nM for binary DNP, ~23 nM for ternary), while fluorescence polarization and limited trypsin proteolysis confirmed conformational changes upon RNA recruitment. Kinetics revealed a catalytic rate (k_cat ~0.40 min⁻¹) comparable to RNA-guided systems, albeit slightly slower due to lacking RNA stabilization. Critically, the system demonstrates RNA specificity: no binding or activation with ssDNA or dsDNA targets, distinguishing it from canonical configurations.

Specificity testing across eight orthogonal crDNA-RNA pairs and single-nucleotide mismatch scans highlighted seed-region sensitivity, with truncating spacers to 16 nt enhancing discrimination up to 7-fold. This precision rivals Cas13 RNA-targeting systems while leveraging Cas12a's smaller size and collateral activity.

Experimental Validation: High Efficiency and Specificity in Lab and Cells

In vitro, the DNA-guided Cas12a cleaved 450-nucleotide ssRNAs robustly across orthologs like LbCas12a and LbaCas12a. Trans-cleavage of fluorogenic reporters enabled picomolar RNA detection without amplification, a boon for point-of-care tools. In human HEK293T cells, phosphorothioate (PS)-modified crDNAs achieved 76% knockdown of EGFP mRNA and 56% protein reduction, with RNA-seq confirming minimal off-targets—far superior to unmodified guides.

Endogenous mouse Mif knockdown further proved programmability, with no activity from mismatched crDNAs. Toxicity assays showed low cell viability impact, positioning this for therapeutic use. These results stem from meticulous optimization, including PS modifications for nuclease resistance and 2:1 Cas12a:crDNA ratios for maximal complex formation.

SLEUTH: A Revolutionary Diagnostic Platform

Building on trans-cleavage, the team unveiled SLEUTH—a recombinase polymerase amplification (RPA)/reverse transcription-RPA coupled with T7 transcription and DNA-guided Cas12a readout. This one-pot assay detects attomolar (1 aM) RNA or DNA, outperforming RNA-guided methods in reagent stability. Tested on 31 SARS-CoV-2 clinical samples, it matched RT-qPCR with 100% concordance, distinguishing variants rapidly. For resource-limited settings, SLEUTH's isothermal nature and DNA guide durability promise widespread adoption, especially amid viral threats.Learn more about the SLEUTH platform in the original study.

HKUST's Role in China's Biotech Renaissance

HKUST, consistently ranked among Asia's top universities (44th QS World 2026, #1 Hong Kong), excels in life sciences with its interdisciplinary Division of Life Science and Chemical Engineering synergy. Professor Hsing's lab exemplifies this, securing funding from Hong Kong's Research Grants Council and China's NSFC. This paper marks a milestone, enhancing HKUST's reputation alongside prior CRISPR innovations like Cas12a diagnostics.

In China, where higher education invests billions in biotech (e.g., national labs, Thousand Talents), HKUST's work aligns with priorities like RNA therapeutics and diagnostics. Universities like Tsinghua and Peking lead in CRISPR patents, but HKUST's modular approach could accelerate antiviral platforms amid pandemics.

Implications for Therapeutics and Synthetic Biology

Beyond diagnostics, DNA-guided Cas12a enables precise RNA knockdown without Cas13's high toxicity. Targeting viral mRNAs or disease transcripts (e.g., in cancer, neurodegeneration) becomes feasible. The modular design—DNA for activation, RNA for specificity—allows multiplexing via orthogonal crDNAs, ideal for synthetic circuits.

In therapeutics, PS-crDNAs could deliver transient knockdown, minimizing genomic risks. Live-cell imaging via fused reporters hints at dynamic RNA tracking. Compared to siRNA or ASOs, CRISPR's programmability offers reversibility and multiplexing advantages.

Challenges and Future Directions

• Enhance delivery: Viral vectors or LNPs for in vivo crDNA-Cas12a.
• Expand orthologs: Test FnCas12a for broader PAMs.
• Multiplexing: Arrayed crDNAs for high-throughput screening.
• Clinical translation: Preclinical antiviral models, e.g., SARS-CoV-2.

Off-target minimization via shorter spacers and AI design tools will be key. Collaborations with mainland China firms like BGI could fast-track commercialization.

Career Opportunities in CRISPR Research at Chinese Universities

This innovation spotlights booming opportunities in China's biotech ecosystem. HKUST and peers seek postdocs, faculty in CRISPR engineering—check research jobs. With NSFC grants surging, roles span synthetic biology to diagnostics. For aspiring researchers, HKUST's MSc in Biomolecular Engineering offers hands-on training.Explore Professor Hsing's lab.

In summary, HKUST's DNA-guided CRISPR-Cas12a redefines RNA manipulation, blending academic excellence with real-world impact. As China cements biotech leadership, such university innovations promise to reshape medicine and beyond.

Photo by Karl Solano on Unsplash